The Glucosamine-study: The Effect of Glucosamine in Treatment of Chronic Low Back Pain

NCT00404079 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 250

Last updated 2011-04-29

Study results available
· View outcomes & findings →

Summary

Low back pain (LBP) is the most frequent cause of sick leave and disability pension, and degenerative and osteoarthritic (OA) changes is a significant cause of pain and disability. Some indications exist for symptomatic and possible cartilage-structurmodifying effect on knee- and hip-osteoarthritis with glucosamine sulphate (GS). The OA process in the lumbar spine is most likely to OA processes in knees and hips, hence GS could have comparable symptomatic and structural effect on lumbar OA.

Study hypothesis: No difference in treatment effect exists between oral intake of GS- or placebo-capsules for patients' with chronic low back pain measured with Roland Morris Disability Questionnaire.

Conditions

  • Low Back Pain

Interventions

DRUG

Glucosamine sulphate

Oral intake of 1500 mg glucosamine sulfate(from Pharma Nord) daily for 6 months

DRUG

Placebo

Oral intake of 3 placebo capsules (similiar looking to the glucosamine sulfate capsules)daily for 6 months

Sponsors & Collaborators

  • Stiftelsen Helse og Rehabilitering

    collaborator OTHER
  • Ullevaal University Hospital

    lead OTHER

Principal Investigators

  • Oliver Grundnes, MD · Ullevaal University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
25 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2006-12-31
Primary Completion
2009-08-31
Completion
2010-11-30

Countries

  • Norway

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00404079 on ClinicalTrials.gov